CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 493 enrolled
Drug / intervention
Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension +3 moredrug
Likely dose
Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspensionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02339584
NCT02339584Phase 3Completed
CompareCT.gov

Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research·interventional·Posted Jan 15, 2015·Updated Jul 2, 2018

In Brief

A Phase 3 clinical trial evaluating Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, Brinzolamide 10 mg/mL eye drops, suspension, and 2 other interventions for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 493 participants.

Detailed Summary

The purpose of this study is to compare the fixed combination (BID) \[Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL eyes drops, suspension\] to the unfixed combination (BID) \[Brinzolamide 10 mg/mL eye drops, suspension plus Brimonidine 2 mg/mL eyes drops, solution\] with respect to intraocular pressure (IOP)-lowering efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 15, 2015
Enrollment StartApr 14, 2015
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.5 years ago

Interventions

Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspensiondrug

Brinzolamide 10 mg/mL eye drops, suspensiondrug

Brimonidine 2 mg/mL eye drops, solutiondrug

Vehicledrug

Inactive ingredients used as a placebo for masking purposes